These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia. Liu W; Liu K; Wood HB; McCann ME; Doebber TW; Chang CH; Akiyama TE; Einstein M; Berger JP; Meinke PT J Med Chem; 2009 Jul; 52(14):4443-53. PubMed ID: 19530681 [TBL] [Abstract][Full Text] [Related]
24. Single gene contributions: genetic variants of peroxisome proliferator-activated receptor (isoforms alpha, beta/delta and gamma) and mechanisms of dyslipidemias. Yong EL; Li J; Liu MH Curr Opin Lipidol; 2008 Apr; 19(2):106-12. PubMed ID: 18388689 [TBL] [Abstract][Full Text] [Related]
25. The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities. Einstein M; Akiyama TE; Castriota GA; Wang CF; McKeever B; Mosley RT; Becker JW; Moller DE; Meinke PT; Wood HB; Berger JP Mol Pharmacol; 2008 Jan; 73(1):62-74. PubMed ID: 17940191 [TBL] [Abstract][Full Text] [Related]
26. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair. Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600 [TBL] [Abstract][Full Text] [Related]
27. Predictive value of interleukin-10 promoter genotypes and haplotypes in determining the susceptibility to nephropathy in type 2 diabetes patients. Mtiraoui N; Ezzidi I; Kacem M; Ben Hadj Mohamed M; Chaieb M; Haj Jilani AB; Mahjoub T; Almawi WY Diabetes Metab Res Rev; 2009 Jan; 25(1):57-63. PubMed ID: 19031431 [TBL] [Abstract][Full Text] [Related]
28. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo. Hsu MC; Huang CC; Chang HC; Hu TH; Hung WC Clin Cancer Res; 2008 Jul; 14(13):4045-52. PubMed ID: 18593980 [TBL] [Abstract][Full Text] [Related]
29. Further evidence for the association of MMP9 with nephropathy in type 2 diabetes and application of DNA pooling technology to candidate gene screening. Nair S; Phillips AO; Norton N; Spurlock G; Williams HJ; Craig KJ; Williams JD; Williams NM; Bowen T J Nephrol; 2008; 21(3):400-5. PubMed ID: 18587729 [TBL] [Abstract][Full Text] [Related]
30. Peroxisome proliferator-activated receptor-gamma gene polymorphism and risk of cardiovascular disease in patients with diabetic nephropathy. Szeto CC; Chow KM; Poon PY; Kwan BC; Li PK Am J Nephrol; 2008; 28(5):715-22. PubMed ID: 18417957 [TBL] [Abstract][Full Text] [Related]
31. Relationship between peroxisome proliferator-activated receptor-gamma activation and the ameliorative effects of ascochlorin derivatives on type II diabetes. Magae J; Tsuruga M; Maruyama A; Furukawa C; Kojima S; Shimizu H; Ando K J Antibiot (Tokyo); 2009 Jul; 62(7):365-9. PubMed ID: 19557028 [TBL] [Abstract][Full Text] [Related]
32. Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan. Kühne A; Kaiser R; Schirmer M; Heider U; Muhlke S; Niere W; Overbeck T; Hohloch K; Trümper L; Sezer O; Brockmöller J Pharmacogenet Genomics; 2007 Jul; 17(7):505-17. PubMed ID: 17558306 [TBL] [Abstract][Full Text] [Related]